Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
Public ClinicalTrials.gov record NCT00978497. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Trial of the Safety, Efficacy, and Pharmacokinetics of ANA598 Administered With Pegylated Interferon and Ribavirin in Treatment-Naïve Genotype 1 Patients With Chronic Hepatitis C Infection
Study identification
- NCT ID
- NCT00978497
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 97 participants
Conditions and interventions
Conditions
Interventions
- placebo Drug
- ANA598 Drug
- Peginterferon Drug
- Ribavirin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2009
- Primary completion
- Mar 31, 2010
- Completion
- Jul 31, 2011
- Last update posted
- Mar 30, 2017
2009 – 2011
United States locations
- U.S. sites
- 20
- U.S. states
- 11
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| United States, California 1 | Anaheim | California | 92801 | — |
| United States, California 4 | Los Angeles | California | 90048 | — |
| United States, California 2 | San Clemente | California | 92673 | — |
| United States, California 3 | San Diego | California | 92120 | — |
| United States, California 5 | San Francisco | California | 33136 | — |
| United States, Florida 2 | Gainesville | Florida | 32601 | — |
| United States, Florida 3 | Miami | Florida | 33136 | — |
| United States, Florida 1 | Sarasota | Florida | 34209 | — |
| United States, Maryland | Lutherville | Maryland | 21093 | — |
| United States, Massachusetts | Boston | Massachusetts | 02215 | — |
| United States, Michigan | Detroit | Michigan | 48202 | — |
| United States, New York | New York | New York | 10021 | — |
| United States, North Carolina | Chapel Hill | North Carolina | 27514 | — |
| United States, North Carolina | Durham | North Carolina | 27705 | — |
| United States, Ohio | Cincinnati | Ohio | 45267 | — |
| United States, Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| United States, Texas 2 | Houston | Texas | 77073 | — |
| United States, Texas 1 | San Antonio | Texas | 78215 | — |
| United States, Virginia 1 | Fairfax | Virginia | 22031 | — |
| United States, Virginia 2 | Falls Church | Virginia | 22042 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00978497, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 30, 2017 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00978497 live on ClinicalTrials.gov.